MD Anderson, MedImmune join forces to advance cancer immunotherapy

The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news